Target intelligence / Profile preview

Human gut microbiota (GM) (GM)

Target
GM
Molecular classification
Other (Biological Ecosystem)
01

Overview

The human gut microbiota is a complex and dynamic ecosystem comprising trillions of microorganisms, including bacteria, archaea, fungi, and viruses, that reside within the gastrointestinal tract. This community acts as a functional "organ," playing a pivotal role in host physiology by fermenting dietary fibers into short-chain fatty acids, synthesizing essential vitamins, and regulating the development and activity of the host immune system (Nature Reviews Microbiology, 2022). Dysbiosis, or the pathological imbalance of this microbial community, is strongly associated with various diseases, including Clostridioides difficile infection (CDI), inflammatory bowel disease (IBD), and metabolic syndromes (NIH, 2023). Therapeutic strategies targeting the gut ecosystem include the use of live biotherapeutic products (LBPs) such as Vowst and Rebyota, which are designed to restore microbial diversity and outcompete pathogens (FDA, 2023). Additionally, the gut microbiome influences the pharmacokinetics and efficacy of various systemic drugs, making it a critical consideration in personalized medicine and the emerging field of the gut-brain axis.

Other names
Gut microbiomeIntestinal microbiotaGut floraGastrointestinal ecosystemMicrobial community
02

Mechanism of action

Restoration of microbial diversity, competitive exclusion of pathogens, and modulation of host metabolic and immune pathways via microbial metabolites.

03

Biological functions

MetabolismImmune responsePathogen defenseVitamin synthesisSignal transduction (Gut-brain axis)
04

Disease associations

Infection (Clostridioides difficile)Inflammation (IBD)Metabolic disease (Obesity/Diabetes)Cancer (Colorectal)Neurodegenerative disease
05

Safety considerations

Risk of pathogen transmissionBacteremia in immunocompromised patientsUnintended long-term metabolic consequencesLack of product standardization
06

Interacting drugs

Fecal microbiota spores, live-brpk (Vowst)

5 more in the full profile.

07

Biomarkers

Alpha diversity (Shannon index)Beta diversityFirmicutes/Bacteroidetes ratioFecal calprotectin

Beyond the preview

Go deeper on Human gut microbiota (GM) (GM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human gut microbiota (GM) (GM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call